Trademark Search in Canada

VERTEX CELL AND GENETIC THERAPIES

View On IC.GC.CA

ADVERTISED

on 29 Jan 2025

Last Applicant/ Owned by

Vertex Pharmaceuticals Incorporated

50 Northern AvenueBoston, MA 02210

Serial Number

2050344 filed on 9^th Sept 2020

Correspondent Address

DLA PIPER (CANADA) LLP

BAY ADELAIDE - WEST TOWERSUITE 5100 - 333 BAY STREETTORONTO

ONTARIO

M5H2R2

VERTEX CELL AND GENETIC THERAPIES

Trademark usage description

house mark for pharmaceutical preparations used to treat genetic diseases and disorders, pharmaceutical preparations used to treat muscular dystrophy, Read More

Classification Information

Class [005]
House mark for pharmaceutical preparations used to treat genetic diseases and disorders, pharmaceutical preparations used to treat muscular dystrophy, pharmaceutical preparations used to treat sickle cell disease, pharmaceutical preparations used to treat beta thalassemia, pharmaceutical preparations used to treat cystic fibrosis, pharmaceutical preparations used to treat Alpha-1 antitrypsin deficiency, pharmaceutical preparations used to treat lung diseases, pharmaceutical preparations used to treat liver diseases, pharmaceutical preparations used to treat kidney diseases, pharmaceutical preparations used to treat autoimmune diseases, pharmaceutical preparations used to treat pain; nucleic acid medicines for the treatment of genetic diseases and disorders; pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations for the treatment of muscular dystrophy

Classification kind code

Class [042]
Medical and scientific research in the field of gene therapy; medical and scientific research in the field of nucleic acid; medical and scientific research in the field of gene editing for developing cells and pharmaceuticals for medical and clinical use; research and development of pharmaceuticals using gene editing.

Classification kind code

Mark Details

Serial Number

2050344

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 42 on 29^th Jan 2025	Advertised
Submitted for opposition 26 on 1^st Jan 2025	Approved
Submitted for opposition 27 on 1^st Jan 2025	Approval Notice Sent
Submitted for opposition 22 on 20^th Aug 2024	Search Recorded
Submitted for opposition 20 on 20^th Aug 2024	Examiner's First Report
Submitted for opposition 287 on 20^th Apr 2022	Pre-Assessment Letter Sent
Submitted for opposition 30 on 9^th Sept 2020	Filed
Submitted for opposition 1 on 9^th Sept 2020	Created
Submitted for opposition 31 on 9^th Sept 2020	Formalized